Similarity between the in vitro activity and toxicity of two different fungizone™ / lipofundin™ admixtures

Amphotericin B (AmB), an antifungal agent that presents a broad spectrum of activity, remains the gold standard in the antifungal therapy. However, sometimes the high level of toxicity forbids its clinical use. The aim of this work was to evaluate and compare the efficacy and toxicity in vitro of Fungizon™ (AmB-D) and two new different AmB formulations. Methods: three products were studied: Fungizon™, and two Fungizon™ /Lipofundin™ admixtures, which were diluted through two methods: in the first one, Fungizon™ was previously diluted with water for injection and then, in Lipofundin™ (AmB-DAL); the second method consisted of a primary dilution of AmB-D as a powder in the referred emulsion (AmB-DL). For the in vitro assay, two cell models were used: Red Blood Cells (RBC) from human donors and Candida tropicallis (Ct). The in vitro evaluation (K+ leakage, hemoglobin leakage and cell survival rate-CSR) was performed at four AmB concentrations (from 50 to 0.05mg.L-1). Results: The results showed that the action of AmB was not only concentration dependent, but also cellular type and vehicle kind dependent. At AmB concentrations of 50 mg.L-1, although the hemoglobin leakage for AmB-D was almost complete (99.51), for AmB-DAL and AmB-DL this value tended to zero. The p = 0.000 showed that AmB-D was significantly more hemolytic. Conclusion: The Fungizon™- Lipofundin™ admixtures seem to be the more valuable AmB carrier systems due to their best therapeutic index presented

Cloud query manager: uso de web semântica para evitar o problema de aprisionamento em IaaS

Cloud computing can be defined as a distributed computational model by through resources (hardware, storage, development platforms and communication) are shared, as paid services accessible with minimal management effort and interaction. A great benefit of this model is to enable the use of various providers (e.g a multi-cloud architecture) to compose a set of services in order to obtain an optimal configuration for performance and cost. However, the multi-cloud use is precluded by the problem of cloud lock-in. The cloud lock-in is the dependency between an application and a cloud platform. It is commonly addressed by three strategies: (i) use of intermediate layer that stands to consumers of cloud services and the provider, (ii) use of standardized interfaces to access the cloud, or (iii) use of models with open specifications. This paper outlines an approach to evaluate these strategies. This approach was performed and it was found that despite the advances made by these strategies, none of them actually solves the problem of lock-in cloud. In this sense, this work proposes the use of Semantic Web to avoid cloud lock-in, where RDF models are used to specify the features of a cloud, which are managed by SPARQL queries. In this direction, this work: (i) presents an evaluation model that quantifies the problem of cloud lock-in, (ii) evaluates the cloud lock-in from three multi-cloud solutions and three cloud platforms, (iii) proposes using RDF and SPARQL on management of cloud resources, (iv) presents the cloud Query Manager (CQM), an SPARQL server that implements the proposal, and (v) comparing three multi-cloud solutions in relation to CQM on the response time and the effectiveness in the resolution of cloud lock-in.

Similarity between the in vitro activity and toxicity of two different fungizone™ / lipofundin™ admixtures

Amphotericin B (AmB), an antifungal agent that presents a broad spectrum of activity, remains the gold standard in the antifungal therapy. However, sometimes the high level of toxicity forbids its clinical use. The aim of this work was to evaluate and compare the efficacy and toxicity in vitro of Fungizon™ (AmB-D) and two new different AmB formulations. Methods: three products were studied: Fungizon™, and two Fungizon™ /Lipofundin™ admixtures, which were diluted through two methods: in the first one, Fungizon™ was previously diluted with water for injection and then, in Lipofundin™ (AmB-DAL); the second method consisted of a primary dilution of AmB-D as a powder in the referred emulsion (AmB-DL). For the in vitro assay, two cell models were used: Red Blood Cells (RBC) from human donors and Candida tropicallis (Ct). The in vitro evaluation (K+ leakage, hemoglobin leakage and cell survival rate-CSR) was performed at four AmB concentrations (from 50 to 0.05mg.L-1). Results: The results showed that the action of AmB was not only concentration dependent, but also cellular type and vehicle kind dependent. At AmB concentrations of 50 mg.L-1, although the hemoglobin leakage for AmB-D was almost complete (99.51), for AmB-DAL and AmB-DL this value tended to zero. The p = 0.000 showed that AmB-D was significantly more hemolytic. Conclusion: The Fungizon™- Lipofundin™ admixtures seem to be the more valuable AmB carrier systems due to their best therapeutic index presented